Skip to main content
AAA 2024+HearTECH Expo Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Tier 1
Tier 1
Ethics
Ethics
HearTECH Hub
HearTECH Hub
Ticket Required
Ticket Required
Back

Tinnitus and Decreased Sound Tolerance (TH)

IU223 - Lenire Tinnitus Treatment Real World Success

Friday, April 19, 2024
1:35 PM – 2:05 PM EST
Location: IU Room 7
Earn 0.05 CEUs
Instructional Level: Fundamental

    Lead Presenter(s)

  • Tish Ramirez, AuD (she/her/hers)

    Global Commercialization Officer / Chief Commercial Officer US
    Neuromod USA, Incorporated

    Disclosure(s): Neuromod USA, Incorporated: Employment (Ongoing)

    • Presenter(s)

  • Cheri Hebeisen, AuD (she/her/hers)

    Manager, Clinical Training and Business Development
    Neuromod
    Lisle, Illinois

    Disclosure(s): Neuromod USA, Incorporated: Employment (Ongoing)

Abstract: Tinnitus, a common global health issue affecting life quality and mental well-being, has a new solution: Lenire. This at-home device, the first to receive FDA approval for tinnitus treatment, uses bimodal neuromodulation to alleviate symptoms. Following a large-scale, FDA-compliant clinical trial where 83% of participants recommended it, Lenire has shown consistent positive outcomes in both clinical and real-world settings, marking a significant advancement in tinnitus treatment.

Learning Objectives:

  • Attendees will be able to summarize real-world results with the Lenire tinnitus treatment device.
  • Attendees will be able to explain the concept of bimodal neuromodulation as it relates to tinnitus treatment.
  • Attendees will be able to summarize results of clinical trials demonstrating use of bimodal neuromodulation to treat tinnitus.